Cupid Ltd shares have witnessed significant momentum following recent promoter stake acquisitions by Chairman and Managing Director Aditya Kumar Halwasiya. On August 17, Halwasiya purchased 13,95,538 equity shares representing 0.10% stake in the company through open market transactions, according to exchange filings. The promoter acquired an additional 0.06% stake, or 8,03,000 Cupid shares on August 18 via open market transactions. With these acquisitions, Halwasiya's personal shareholding in the company rose to 33.45%, while the aggregate shareholding of the promoter and promoter group in Cupid stood at 46.40%. The stock has already surged over 36% in one month and had touched a 52-week high of ₹298.95 on August 14, 2026, before witnessing profit booking at higher levels after two straight days of rally.
Cupid Ltd has delivered exceptional returns to investors across all timeframes, establishing itself as a multibagger stock. The stock has surged 137% in three months, 233% in six months, and jumped nearly 750% in one year. More remarkably, the stock has generated stellar growth of nearly 12,150% over the past five years. As per NDTV Profit reports, the stock touched an intraday high of ₹286.80 on Thursday, rising nearly 0.9% from its previous closing price, before profit booking at higher levels. At 1:25 PM, Cupid share price was trading 0.70% lower at ₹282.30 on the BSE. The recent gains have come amid the promoter raising stake in the condom maker, putting the company back on investors' radar.
Despite the recent price decline, Cupid Ltd delivered exceptional financial performance in Q1FY27. As reported by Goodreturns, the company posted 142% YoY growth in total income to ₹156.98 crore, while EBITDA skyrocketed by 265% YoY to ₹154.72 crore. Net profit climbed 194% YoY to ₹44.15 crore in the quarter. EBITDA margins expanded strongly by 1,127 basis points to 39% compared to the year-ago quarter. The company commenced FY27 with strong momentum across international B2B healthcare and domestic Consumer Healthcare & FMCG businesses, supported by healthy execution across key operating segments. The strong increase in revenue was accompanied by significant improvement in operating profitability, with the company reporting an improvement of 1,127 basis points in the margin, indicating stronger operating leverage and a favourable contribution from its business mix.
The company has set a higher financial target for FY27, raising its revenue guidance to ₹725-750 crore. Cupid has also projected profit of ₹210-225 crore for the financial year, supported by factors including its order pipeline, international business, manufacturing expansion and the growing contribution from its Consumer Healthcare and FMCG operations. The company is attempting to build a broader business beyond its traditional condom manufacturing operations. Its portfolio now includes male and female condoms, personal lubricants, in-vitro diagnostic kits and FMCG products, giving it exposure to both institutional healthcare requirements and consumer markets. Management's outlook is supported by the company's diversified product portfolio and expanding operational capabilities across multiple healthcare segments.
As of August 18, 2026, Cupid Ltd shares were trading at ₹282.30 on BSE, with the stock showing significant volatility amid the recent promoter activity. The company's 52-week high stands at ₹299.00 while the 52-week low is ₹32.87, indicating substantial price movement over the past year. The stock's market capitalization stands at ₹36,768.41 crore as of the latest trading session. Key valuation metrics show the stock trading at a PE ratio of 264.02 and a PB ratio of 79.74, reflecting the company's premium valuation in the current market conditions. The large transaction involving Cupid has put the company back on investors' radar, particularly because of its size relative to the company's equity base.
